{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-011154","form_type":"8-K","ticker":"ZVRA","cik":"0001434647","company_name":"ZEVRA THERAPEUTICS, INC.","filed_at":"2023-04-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.854644+00:00","generated_at":"2026-06-16T12:28:13.601312+00:00","sec_items":["5.07"],"event_type":"leadership","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Zevra Therapeutics dissident slate wins board seats; three new directors elected","bullets":["Mangless-nominated directors Bode, Calder, Watton elected; company nominees Pascoe, Posner, Tierney received 3.3M, 2.7M, and 2.5M for votes vs 14.2M, 14.8M, and 15.0M withheld.","Ratification of Ernst & Young as auditor approved with 16.3M for vs 0.3M against and 0.9M abstentions.","Mangless Proposal to repeal bylaw changes adopted after Jan 1, 2023 passed (14.5M for, 2.9M against); no such changes existed, so it had no effect.","Turnout: 50.73% of outstanding shares (17.5M of 34.5M) represented at the meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-011154","json":"https://secwatch.observer/filing/0001437749-23-011154.json","markdown":"https://secwatch.observer/filing/0001437749-23-011154.md","text":"https://secwatch.observer/filing/0001437749-23-011154.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434647/000143774923011154/0001437749-23-011154-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434647/000143774923011154/zvra20230426_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T12:28:13.601312+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2a38dfbbc74758a7be9f3bcaa59915248134b1a6","claim":"ZEVRA THERAPEUTICS, INC. shareholders approved Ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023 at the 2023-04-25 meeting.","evidence_excerpt":"the stockholders of the Company ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434647/000143774923011154/0001437749-23-011154-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-04-25"}],"fact_type":"shareholder_vote"},{"claim_id":"7ae3dad2632d151985a0b7f680367b4e66586171","claim":"ZEVRA THERAPEUTICS, INC. shareholders approved Election of three Class II directors to the Company’s board of directors to hold office until the 2026 annual meeting of stockholders at the 2023-04-25 meeting.","evidence_excerpt":"each of John B. Bode, Douglas W. Calder, and Corey Watton was elected as a director of the Company","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434647/000143774923011154/0001437749-23-011154-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-04-25"}],"fact_type":"shareholder_vote"},{"claim_id":"c985f28302d3e34f6e13af13fa97eda9cb609f2b","claim":"ZEVRA THERAPEUTICS, INC. shareholders approved The Mangless Proposal to adopt a resolution that would repeal any provision of the Company’s Amended and Restated Bylaws in effect at the time of the Annual Meeting that was not included in the Company’s Amended and Restated Bylaws in effect as of January 1, 2023 (other than the change of the Compan at the 2023-04-25 meeting.","evidence_excerpt":"Finally, the Mangless Proposal to adopt a resolution that would repeal any provision of the Company’s Amended and Restated Bylaws in effect at the time of the Annual Meeting that was not included in the Company’s Amended and Restated Bylaws in effect as of January 1, 2023 (other than the change of the Company’s name) was approved","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434647/000143774923011154/0001437749-23-011154-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"charter amendment"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-04-25"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}